About Mirvie
Mirvie is a Healthcare company based in San Francisco (United States) founded in 2019 by Mads Melbye, Stephen Quake, and Maneesh Jain. Non-invasive blood tests for prenatal fetal health predictions are offered. It operates on a HealthTech model. Mirvie has raised $113.7 million across 5 funding rounds from investors including Comerica, BlackRock and Khosla Ventures. The company has 35 employees. Its chief executive, as recorded, is Maneesh Jain. Mirvie offers products and services including Mirvie RNA Platform and Encompass Test. Its focus areas include Biotechnology and Pregnancy Health Solutions. Its legal entity is Mirvie, Inc. Its competitors include Sera Prognostics, OncoCyte and Epic Sciences; 2 of its 3 listed competitors have raised funding.
Company details
Mirvie is engaged in developing advanced health technology solutions for pregnancy care. The companys core offering, the Mirvie RNA Platform, uses a simple blood test to analyze tens of thousands of RNA messages, predicting complications like preeclampsia and preterm birth months in advance. Research and clinical validation are conducted to enhance the platforms capabilities. The solutions are aimed at enabling proactive and personalized care for pregnant women. The focus is placed on transforming pregnancy health by providing early insights into unique biological changes. The sector primarily served is healthcare, with an emphasis on maternal and fetal well-being.
- Headquarters San Francisco, United States
- Employees 35
- Founders Mads Melbye, Stephen Quake, Maneesh Jain
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mirvie.com
- Social LinkedIn X Facebook Instagram
- Legal Name Mirvie, Inc.
- Total Equity Funding$113.7M (USD)
in 5 rounds
- Latest Funding Round$23.7M (USD), Series B
Jul 2025
- InvestorsComerica
& 8 more
- Employee Count35
Products & Services of Mirvie
Mirvie offers a comprehensive portfolio of products and services, including Mirvie RNA Platform and Encompass Test.
A platform predicting pregnancy complications using blood tests.
A test providing personalized insights into pregnancy health.
Funding Insights of Mirvie
Mirvie has successfully raised a total of $113.7M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $23.7 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $113.7M
- Total Rounds 5
- Last Round Series B — $23.7M
- First Round $30M
(Apr 2021)
- Investors Count 9
All 5 funding rounds of Mirvie with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $23.7M | Series B | – | – | – |
| Aug 2023 | $4.6M | Grant | – | – | |
| May 2022 | Debt – Conventional | – | – | ||
| May 2022 | $60M | Series B | – | Decheng Capital | |
| Apr 2021 | $30M | Series B | – | Mayfield, Khosla Ventures | – |
9 investors in total: 9 institutional.
Investors in Mirvie
Mirvie has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Comerica, BlackRock and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Investment and transformation services for entrepreneurs in technology and finance sectors. | generalcatalyst.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Mayfield is focused on AI innovation and venture capital investments. | mayfield.com | Menlo Park, United States | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Commercial banking services are provided to businesses and individuals. | 1849 | comerica.com | Dallas, United States | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States |
Investor details for Mirvie
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mirvie
23 people are tracked at Mirvie (15 in leadership, 2 in board & advisors, 6 in team); the tracked headcount is 35.
| Name | Role | Group |
|---|---|---|
Mads Melbye | Co-Founder | Leadership |
Stephen Quake | Co-Founder | Leadership |
Maneesh Jain | Co-Founder & CEO | Leadership |
Manfred Lee | Chief Operating Officer | Leadership |
Michal Elovitz | Chief Medical Advisor | Leadership |
Mitsu Reddy | R&d Director | Leadership |
Thomas McElrath | Vice President Of Clinical Development | Leadership |
Morten Rasmussen | Vice President Research | Leadership |
Elaine Gee | Head, Data Science | Leadership |
Kate Enos | Director Of Communications And Public Relations | Leadership |
Jean Yee | Head Of Finance | Leadership |
Reece MacDonald | Head Of Marketing | Leadership |
Susan Hahn | Head Of Market Access | Leadership |
Alison Moe | Vice President Clinical Operations | Leadership |
Aimee Corso | Senior Vice President, Growth | Leadership |
Naomi Kelman | Board Member | Board & advisors |
Stanley Lapidus | Chairman | Board & advisors |
Eugeni Namsaraev | SVP, Research & Development | Team |
Honiko Morrison | Senior Manager Client Services | Team |
Nathaniel Delaney-Busch | Principal Data Scientist | Team |
3 more people are available in the full profile.
Complete people profiles for Mirvie
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mirvie
3 dated milestones of Mirvie across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Mirvie is founded.
- Funding First funding round of $30.0M.
- Funding Latest funding round, Series B, of $23.7M.
Competitors of Mirvie
Mirvie has 3 listed competitors in our database, 2 of them funded. They include Sera Prognostics, OncoCyte and Epic Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| seraprognostics.com | 2008 | Salt Lake, United States | 123 | Sera Prognostics is focused on women's health diagnostics. | ||
| oncocyte.com | 2009 | Irvine, United States | $15.35M | 76 | Non-invasive diagnostic test solutions for cancer treatment are developed. | |
| epicsciences.com | 2008 | San Diego, United States | $204.5M | 98 | Non-invasive tests for detecting circulating tumor cells are provided. |
Detailed competitors of Mirvie
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mirvie
The website of Mirvie (mirvie.com) receives about 4.2K visits a month.
- Monthly visits4.2K
▲ 8.9% vs previous month
Websites whose visitors overlap most with Mirvie. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sjcms.org | sjcms.org | 100% | #7,240,640 | – | |
studypk.com | studypk.com | 94% | #4,778,831 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Mirvie (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mirvie
Complete news archive for Mirvie
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mirvie
Mirvie was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Mirvie is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Maneesh Jain is the CEO of Mirvie, as recorded in our data. They have also founded this company.
Mirvie is a funded company, having raised a total of $113.7M across 5 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Apr 2021.
Mirvie has 35 employees.
Mirvie is engaged in developing advanced health technology solutions for pregnancy care. The companys core offering, the Mirvie RNA Platform, uses a simple blood test to analyze tens of thousands of RNA messages, predicting complications like preeclampsia and preterm birth months in advance. Research and clinical validation are conducted to enhance the platforms capabilities. The solutions are aimed at enabling proactive and personalized care for pregnant women. The focus is placed on transforming pregnancy health by providing early insights into unique biological changes. The sector primarily served is healthcare, with an emphasis on maternal and fetal well-being.
Mirvie's top competitors include OncoCyte, Epic Sciences and Sera Prognostics.
Mirvie offers Mirvie RNA Platform and Encompass Test.
Mirvie has 9 investors. Key investors include Comerica, BlackRock, Khosla Ventures, Gates Foundation, and Decheng Capital.
Mirvie operates through Mirvie, Inc..